Remdesivir

remdesivir is being evaluated in a WHO-sponsored treatment trial alongside MBP134 in the current Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo and Uganda. The trial is pending regulatory approval from both governments before dosing can begin. Although remdesivir has not previously been licensed for Ebola, its broad antiviral mechanism makes it a candidate for study alongside antibody treatments that are also unapproved for Bundibugyo specifically.

remdesivir is an antiviral medicine developed by Gilead Sciences that works by interfering with viral RNA replication. It was originally investigated as a treatment for hepatitis C and Ebola but gained global recognition during the COVID-19 pandemic, becoming the first antiviral authorised by the US FDA (October 2020) and EU regulators for treating COVID-19 in hospitalised patients. Under the brand name Veklury, it was used in millions of patients worldwide during the pandemic. Its COVID-19 benefit was most clearly demonstrated in patients who received supplemental oxygen, with evidence of reducing hospital stay by several days in controlled trials.

The Bundibugyo study is remdesivir's most prominent Ebola application since early-phase trials before the pandemic. If the WHO trial proceeds and demonstrates efficacy, it would extend remdesivir's established safety profile into Ebola treatment, potentially providing an accessible off-patent-adjacent option in resource-constrained settings where bespoke antibody treatments can be difficult to obtain. The trial design, running remdesivir alongside MBP134 rather than as a standalone Arm, reflects a combination-therapy hypothesis common in antiviral research.